ArticleCureus2026
Seroprevalence and Determinants of Hepatitis B Virus and Hepatitis C Virus Infection Among Pregnant Women in North India: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Maternal hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major contributors to perinatal and early childhood hepatitis transmission in India. Despite national guidelines recommending universal antenatal screening, coverage gaps persist. This study aimed to determine the prevalence, associated risk factors, and preventive outcomes of HBV and HCV among pregnant women in Lucknow District, North India. Objectives The primary objectives of this cross-sectional study were to determine the prevalence of HBV and HCV among pregnant women attending antenatal clinics (ANCs) at primary and secondary health facilities in Lucknow; to assess the risk factors associated with HBV and HCV infection among pregnant women; and to study pregnancy outcomes among HBV/HCV-positive pregnant women. Additionally, we documented whether neonates born to HBV-positive mothers received standard immunoprophylaxis, including hepatitis B immunoglobulin (HBIG) and the hepatitis B birth-dose vaccine. Methods A hospital-based cross-sectional study was conducted among 2005 pregnant women attending ANCs. Serum samples were tested for hepatitis B surface antigen (HBsAg) and anti-HCV antibodies using rapid diagnostic kits at the health facilities, followed by viral load assessment at the Model Treatment Centre (MTC). Sociodemographic, obstetric, and exposure-related data were analyzed using univariate and multivariate logistic regression to identify independent predictors. The timely administration of the hepatitis B birth-dose vaccine and HBIG to neonates born to hepatitis-positive mothers, in accordance with established national protocols, was also documented. Results The overall prevalence of viral hepatitis among pregnant women was 2.8%, including 2.5% HBsAg positivity and 0.3% anti-HCV positivity, with no observed co-infection. Prevalence was higher among women aged ≥25 years. Independent predictors of infection included a sibling history of hepatitis (adjusted odds ratio (AOR) 11.68, p=0.001), unsafe injections administered by unqualified practitioners (AOR 5.07, p=0.024), sharing of sharp instruments such as blades or razors (AOR 5.58, p=0.018), a history of jaundice or prior HBsAg positivity (AOR 5.93, p=0.021), and a family member receiving treatment for HBV or HCV (AOR 15.36, p=0.003). Maternal clinical parameters were reviewed to facilitate appropriate referral and follow-up care in accordance with ethical guidelines. Conclusion This study underscores the importance of universal antenatal screening and regulation of unsafe injection practices. The implementation of comprehensive maternal screening in conjunction with timely neonatal immunoprophylaxis may contribute to reducing vertical transmission and aligns with India's commitment to the World Health Organization's 2030 hepatitis elimination agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.